Adjuvant therapy following breast cancer surgery generally consists of either a course of chemotherapy if the cancer lacks hormone receptors, or a course of hormonal therapy, otherwise.
Introduction
Breast cancer is a highly heterogeneous disease consisting of distinct molecular subtypes having different prognostic and therapeutic responses (1) . Of interest to this manuscript is that surgery is often followed by adjuvant therapy to diminish the chance of recurrence. Chemotherapy is used to stop the growth of cancer cells by either killing them or otherwise halting division (2); hormone therapy lowers estrogen levels or blocks its action (3) . The choice between the two is usually made based on the levels of (4, 5) estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (6) . In general (4) Luminal-A is treated with hormone therapy; luminal B is often treated with chemotherapy, but occasionally with hormone therapy; and HER2 and basil-like subtypes are treated with chemotherapy.
Until now the choice of therapy has been guided by the levels of RNA transcripts of the three hormone receptor genes. Our understanding of cancer biology (7) and the state of computational science (8) (9) (10) (11) (12) (13) (14) (15) has, however, now reached a point where a much fuller profile of the cancer cell can be used to guide the choice of therapy.
The development of cancer is a complex multi-step process that involves accumulation of multiple mutations that lead to dysfunction of cell signaling pathways responsible for cell growth and cell fate (16) . In particular, mutations are not uniformly distributed across different cellular functions, but tend to cluster in a relatively well defined set of physiologically relevant pathways (17) . Consequently it is now generally accepted that causal mechanisms underlying transformation generally reflect the behavior of functionally coupled sets of genes (18) (19) (20) . An analysis of mutational heterogeneity in the context of cellular signaling and regulatory pathways can therefore add to our understanding of cancer progression, and its modulation by different therapeutic strategies (16) .
We identified sets of mutated pathways that are found in a high percentage of TCGA (21) breast cancer samples derived from patients to whom adjuvant therapy had been, or was being, administered. We refer to these pathways as collaborative because they are mutated in a high percentage of the same samples, as opposed to pathways that are altered in different but overlapping sets of samples. This analysis was performed using a recently developed method, Mutational Driver Pathway Collaboration (MUDPAC) (20) . Our goal was to determine whether different therapy groups--the chemotherapy group (CT) and the hormone therapy group (HT) have distinguishing sets of mutated pathways, and if they do, to determine the composition of the two groups. The central result of this paper is that we found strong correlation between altered processes (collaborative pathway groups) and therapy group. This suggests a useful addition to our knowledge of cancer subtypes, and provides a sound molecular basis for subtype recommendations, with perhaps some moderate shifts in recommendations. These observations could have important implications for cancer biology and therapy, which we discuss later. A flowchart of our method can be seen in Figure 1 .
Materials and Methods

Somatic mutation data
Breast cancer tissue somatic mutations (.maf file) were downloaded from TCGA on March, 2013.
All mutations in .maf file are sequenced and annotated before any systemic treatment and therapy (22) .
Tumor sample selection
Tissue sampling is carried out by the TCGA project; no further tissue sampling is performed in this study. Sample subtype information was obtained from the supplementary table of (21) where PAM50 is used to stratify subtypes based on mRNA data. The therapy treatment and drug information of each patient was downloaded from breast cancer TCGA clinical data released in July, 2013. Only chemotherapy and hormone therapy patients are included is this study, which 
MUDPAC
MUDPAC is a method that identifies mutated collaborative pathway-groups, i.e. pathways that are altered in a high percentage of the same samples of a certain cancer or cancer subtype (20) . It consists of two steps. The first step is an identification of pathways showing statistically significant differences between non-synonymous mutation group and synonymous mutation group, based on some characteristics of mutations, such as mutation frequency, functional mutation score, mutual exclusivity, and network topology. The second step uses a greedy search for collaborative pathways. Two more criteria are considered when selecting a new pathway into collaborative set. First, the newly selected pathway along with all pathways already in collaborative set, should have a Maximal Coverage Rate (MCR) higher than the highest mutation rate of genes in this new pathway by a given threshold (3% in this study). Second, permutation is used to test whether MCR of this new pathway is significantly higher than a background MCR (p<0.05 in this study).
Each of the missense mutations in .maf file is assigned a functional mutation score by MutationAssessor (23) based on hg19 reference genome. Since MutationAssessor can only evaluate missense polymorphisms, the functional scores for the remaining mutations are assessed following the same criteria in MUDPAC: the highest score that can be calculated using
MutationAssessor is assigned to all indels, nonsense mutations and splice site mutations; the lowest score from MutationAssessor is allocated to synonymous mutations; the average score of all missense mutations is assigned to other missense mutations that can't be calculated using The Fisher exact test is used to identify KEGG pathways that are statistically enriched in mutated genes of identified pathways compared to the human genome background, and to assess correlations between pathway groups and therapy.
Results
Collaborative pathway groups from hormone therapy and chemotherapy patients are mutually exclusive
Altered physiological functions in CT and HT groups were examined separately using MUDPAC.
We identified 3 collaborative pathways ( All three mutated pathways (PI3K-Akt signaling, p53 signaling, Wnt signaling) in the chemotherapy pathway group (CTPG) are TP53 related. This is consistent with the sample distribution within this therapy group, which has 34 (61%) basal-like samples dominated by the mutated TP53 suppressor gene (21) , which is known to be associated with the basal-like subtype.
In contrast to these three pathways, which play key roles in signal transduction and cell growth The gene sets that trigger pathway dysfunction in the two therapy groups are largely distinct from one other. The top 10 genes with highest mutation frequency in CT and HT are shown in Table 1 .
Of the 10 mutated genes in each group that occur with the highest frequency, 3--TP53, PIK3CA, OBSCN--are common to the two groups. TP53 ranks first with a frequency of 75% in the CT but 10 th (frequency of 8%) in HT. PIK3CA ranks first in HT with a frequency of 53%, but has a frequency of only 18% in CT. OBSCN has comparable mutation rates in the two groups.
However, the mutation type and functional mutational score for OBSCN are different in the two groups. OBSCN has 10 mutations (1 silent, 6 missense mutations, 1 frame shift mutation, 2 nonstop mutations) in CT with an average mutation score of 1.84, but it only has 5 mutations (2 silent mutations, 2 missense mutations, 1 nonsense mutation) in HT with an average functional score of 0.44. This suggests that comparable frequencies do not necessarily imply comparable physiological impact.
We also compared all the genes in the identified pathways of the two therapy groups with 87 plausible breast cancer genes (25) : 37 confirmed drivers, and another 50 driver candidates identified with high likelihood computationally. Of the 532 genes in the CTPG, 27 are among the 87 plausible drivers (Fisher exact test p<10 -15 ). Of the 1059 genes in the HTPG, 40 are among the 87 plausible drivers (Fisher exact test p<10 -15 ). These results suggest that the mutated genes in the identified pathways are highly enriched in drivers. For the two sets of drivers--27 genes for CTPG, and 40 for HTPG --21 are common. The remaining 6 (19) are unique to the chemo (hormone) therapy patients.
Pathway groups are correlates of therapy recommendations
The choice of adjuvant therapy, as noted above, generally follows subtype (4) There are, as expected, strong correlations between the mutated pathway groups seen in patients, and the kind of therapy they receive. The distribution of mutations between HTPG and CTPG for CT patients is highly significant. In particular, the probability that the observed distribution of mutations between the two pathway groups is due to chance, given the patients are in chemotherapy ( Figure 3A ) is p<10 -15 . This follows from a Fisher exact test, based on the observation that for CT, (i) 141 out of 168 (56x3) CTPG pathways are mutated, and 27 are not;
and (ii) 503 of 1120 (56x20) HTPG mutated, and 617 are not ( Figure 3A ; CT columns).
Similar results apply to patients receiving hormone therapy ( Figure 3A ; HT columns): 69 out of 153 (51x3) CTPG pathways are mutated while 84 are not, and 677 out of 1020 (51x20) HTPG pathways are mutated while 343 of them not. The probability that mutations are equally likely in the two pathway groups, given that patients are in hormone therapy is p=4x10 -7 . These results provide a previously unnoticed molecular rationale for the choice of therapy based on cancer subtype. In addition, as discussed below, the structure of Figure 3A 
Pathway groups stratify subtypes
The Luminal-A pattern provides strong statistical evidence that the population of Luminal-A patients in this study can be split into two distinct groups: 29 patients have almost all 20 pathways from HTPG mutated (577 mutated, 3 not), while 17 patients show relatively infrequent mutations (65 mutated, 275 not). The probability that this pattern is the result of chance is p<10 -15 . This again suggests that traditional subtypes can be stratified further, and that higher resolution can be identified by pathway groups. Similarly, although the HER2+ pattern does not support correlation with traditional clinical guidelines for therapy, it does suggest two distinct subpopulations.
Discussion
We demonstrated that HT and CT samples are characterized by mutually exclusive sets of mutated pathways, that are strong correlates of subtype-based therapy recommendation.
Furthermore, genes in these altered pathways are highly enriched in breast cancer drivers and may provide further guidelines for the personalized therapy. Since all the mutations reported in this paper are from DNA sequenced and annotated prior to surgery or therapy, using tissue from the primary tumor at the initial site of the cancer, the results are not a consequence of mutations that might be induced by therapy. 
The discovery that the altered cellular processes that drive transformation in patients having hormone therapy, have a substantially different biology than those that do not, may open an opportunity for the identification of new therapies. Particularly, we found that 100% of the pathways in chemotherapy are TP53 related, while 70% of pathways in hormone therapy are involved in organismal system, especially in immune system (30%) and endocrine system (20%).
Both immune (26, 27) and endocrine systems (28-30) can work primarily through estrogen receptors, regulating cells in pathways from these two systems could therefore lead to the successful development of therapeutic concepts in breast cancer. In brief, we hope our identified pathways could be considered as a signature to classify patients for their treatments in the future, as an auxiliary of current protocol, after we could get enough samples to test. Moreover, The mutated genes in our identified pathways tend to be sample specific ( Figure 3B ). Except for TP53 and PIK3CA, which have the highest mutated rates in chemotherapy (75% in CT and 8% in HT) and hormone therapy (53% in HT and 18% in CT) groups respectively, almost all the other genes are dispersed among samples, even for subtypes that have similar pathway patterns But the mutated genes in these pathways are specific to each patient: there are totally 12 genes mutated in HER2+ (PIK3CA, TP53, ABL2, ATR, NKD2, TXK, XCR1, ADCY8, FLT4, PPP3CA, STAT5B, IRF9), total 15 genes mutated in Luminal-B (PIK3CA, TP53, RPS6KA6, TCF7, FIGF,   PAK7, PIK3R1, BCL2L11, CCNB1, FGFR2, FN1, MYH10, NFATC4, PIK3R3, TRIP10 ). Besides PIK3CA which is mutated in all 7 patients, and TP53 which is mutated in 6 out of 7 patients, all the remaining genes are mutated in only one patient, and no two genes are mutated in the same patient.
The conventional way to determine whether to apply chemo or hormone therapy is according to the breast cancer molecular subtypes, which are induced by gene regulation level of several molecular factors like estrogen receptor, progesterone receptor, and human epidermal growth factor. This strategy has been developed for decades and greatly helped physicians to draw up clinical schemes, which are also evidenced by our identified mutated pathways: different molecular subtypes tend to have distinct mutation patterns, and are approximately concordant with pathways of their recommended therapy groups.
The subtype information including biological process and molecular functions in epigenetic alone, however, may not fully uncover the whole picture. Mutated drivers, including both genes and pathways that initiate cancer development, may supplement this picture. We present in
Results that even for the same subtype like Luminal-A, the mutational landscape is diverse between patients in CT and HT. This may advise that current treatment protocol need to be personalized by integrating genetic factors like driver genes and driver pathways. Taken together, our findings suggest that systematic mutation analysis of breast cancer can reveal pathway dysfunction status and mutated gene portraits that may not easily be discovered in transcriptome level. This brings new insights about personalized treatment and targeted agents. Tables   Table 1. Top 10 highly mutated genes in collaborative pathways of chemotherapy and hormone therapy groups. Genes are listed with mutation frequency descending order, with mutation frequency shown in brackets.
Gene rank Chemotherapy Hormone therapy
Figure Legends groups are mutual exclusive to each other. We hope mutated pathway groups could be considered as a signature in the future to stratify subtypes and optimize therapeutic treatments. 
